Figure 2.

Mean change in ADAS-Cog scores from Baseline in the ITT population w/LOCF and stratified by APOE4 carriage status. Y axis is change from Baseline. X axis is time in days. Red circles and lines represent subjects taking AC-1202. Blue squares and lines represent subjects taking Placebo. Error bars represent standard error of the mean. Asterisks (*) indicate a significant (p-value < 0.05) difference in mean change from Baseline between AC-1202 and Placebo. A) Intention to treat subjects (N = 77AC, N = 63PL) administered AC-1202 demonstrate a significant difference from Placebo at Day 45. B) Genotyped subjects lacking the APOE4 allele (APOE4(-)) (N = 29AC, N = 26PL) and administered AC-1202 demonstrate a significant difference from Placebo at Days 45 and 90. C) Genotyped subjects carrying the APOE4 allele (APOE4(+)) (N = 38AC, N = 31PL) do not differ from Placebo at any time point. For confidence intervals and p-values see Table 5.

Henderson et al. Nutrition & Metabolism 2009 6:31   doi:10.1186/1743-7075-6-31
Download authors' original image